Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Accumulated Expenses (2016 - 2026)

Neuroone Medical Technologies filings provide 13 years of Accumulated Expenses readings, the most recent being $755258.0 for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 11.42% to $755258.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $755258.0, a 11.42% decrease, with the full-year FY2025 number at $1.3 million, up 9.18% from a year prior.
  • Accumulated Expenses hit $755258.0 in Q1 2026 for Neuroone Medical Technologies, up from $706112.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q3 2025 to a low of $41646.0 in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $755258.0 (2026), compared with a mean of $696507.2.
  • Biggest five-year swings in Accumulated Expenses: crashed 93.02% in 2024 and later skyrocketed 1947.22% in 2025.
  • Neuroone Medical Technologies' Accumulated Expenses stood at $473085.0 in 2022, then dropped by 28.03% to $340490.0 in 2023, then surged by 142.7% to $826386.0 in 2024, then fell by 14.55% to $706112.0 in 2025, then grew by 6.96% to $755258.0 in 2026.
  • The last three reported values for Accumulated Expenses were $755258.0 (Q1 2026), $706112.0 (Q4 2025), and $1.3 million (Q3 2025) per Business Quant data.